Treatment decisions and outcomes for NCCN favorable intermediate-risk prostate cancer patients after receiving the 17-gene genomic prostate cancer score result.

Eric Margolis,John M. Bennett,Marina Pavlova,Kenny Wong,Christopher Michael Pieczonka,Benjamin H Lowentritt,Edward Uchio,Melissa Conrad Stöppler

Treatment decisions and outcomes for NCCN favorable intermediate-risk prostate cancer patients after receiving the 17-gene genomic prostate cancer score result.

2021

Eric Margolis
John M. Bennett
Marina Pavlova
Kenny Wong
Christopher Michael Pieczonka
Benjamin H Lowentritt
Edward Uchio
Melissa Conrad Stöppler

218Background: Molecular assays are used to improve risk stratification in prostate cancer. This study determined how the 17-gene Genomic Prostate Score (GPS) assay guides treatment decisions in pa...

Keywords:

Oncology
Prostate cancer
intermediate risk
Gene
treatment decision making
risk stratification
Medicine
Internal medicine
Prostate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations